Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Feb;23(2):245-50.
doi: 10.1038/leu.2008.289. Epub 2008 Oct 16.

Clinical consequences of hyperglycemia during remission induction therapy for pediatric acute lymphoblastic leukemia

J R Roberson  1 , H L Spraker, J Shelso, Y Zhou, H Inaba, M L Metzger, J E Rubnitz, R C Ribeiro, J T Sandlund, S Jeha, C-H Pui, S C Howard
Affiliations

Clinical consequences of hyperglycemia during remission induction therapy for pediatric acute lymphoblastic leukemia

J R Roberson et al. Leukemia. 2009 Feb.

Abstract

Hyperglycemia adversely affects outcome in adult patients with acute lymphoblastic leukemia (ALL), but its impact on children with this disease is unknown. We evaluated the relationship between hyperglycemia during remission induction therapy and clinical outcomes among pediatric patients with ALL. We reviewed the records of patients enrolled on four consecutive ALL protocols (Total Therapy protocols XIIIA, XIIIB, XIV and XV) at St Jude Children's Research Hospital from 1991 to 2007 and identified those who experienced hyperglycemia (glucose >or=200 mg per 100 ml) during remission induction. Complete remission (CR) rates at the end of induction, event-free survival (EFS), overall survival (OS), cumulative incidence of relapse and occurrence of infections were compared between those who did and did not experience hyperglycemia. Of 871 patients analyzed, 141 (16%) experienced hyperglycemia during remission induction. Patients with hyperglycemia were significantly older than the other patients (P<0.0001). There was no significant difference in CR rate (P=0.92), EFS (P=0.80), OS (P=0.28), cumulative incidence of relapse (P=0.59) or in the probability or types of infection between patients who did and did not experience hyperglycemia. Pediatric patients with or without hyperglycemia during remission induction for ALL have similar clinical outcome. Occurrence of hyperglycemia does not warrant alteration of the antileukemic regimen.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Iyer RS, Rao SR, Pai S, Advani SH, Magrath IT. L-asparaginase related hyperglycemia. Indian J Cancer. 1993 Jun;30(2):72–6. - PubMed
    1. Jaffe N, Traggis D, Das L, Frauenberger G, Hann HW, Kim BS, et al. Favorable remission induction rate with twice weekly doses of L-asparaginase. Cancer Res. 1973 Jan;33(1):1–4. - PubMed
    1. Jaffe N, Traggis D, Das L, Kim BS, Won H, Hann L, et al. Comparison of daily and twice-weekly schedule of L-asparaginase in childhood leukemia. Pediatrics. 1972 Apr;49(4):590–5. - PubMed
    1. Lavine RL, DiCinto DM. L-Asparaginase diabetes mellitus in rabbits: differing effects of two different schedules of L-asparaginase administration. Horm Metab Res. 1984 Dec;16(Suppl 1):92–6. - PubMed
    1. Lavine RL, Brodsky I, Garofano CD, Rose LI. The effect of E. coli L-asparaginase on oral glucose tolerance and insulin release in man. Diabetologia. 1978 Aug;15(2):113–6. - PubMed

Publication types

  NODES
admin 1
twitter 2